Journal Articles

2023

  • L. Pulakat, “A role for misaligned gene expression of fetal gene program in the loss of female-specific cardiovascular protection in young obese and diabetic females,” Front Endocrinol (Lausanne), vol. 14, p. 1108449, Feb. 2023, doi: 10.3389/fendo.2023.1108449.
  •  
  • A. Boukhalfa et al., “Using cultured canine cardiac slices to model the autophagic flux with doxorubicin,” PLoS One, vol. 18, no. 3, p. e0282859, Mar. 2023, doi: 10.1371/journal.pone.0282859.
  •  
  • A. M. Belenchia et al., “Cardiovascular Protective Effects of NP-6A4, a Drug with the FDA Designation for Pediatric Cardiomyopathy, in Female Rats with Obesity and Pre-Diabetes,” Cells, vol. 12, no. 10, p. 1373, May 2023, doi: 10.3390/cells12101373.

2022

  • L. Pulakat et al., “Transdermal Delivery of High Molecular Weight Antibiotics to Deep Tissue Infections via Droplette Micromist Technology Device (DMTD),” Pharmaceutics, vol. 14, no. 5, p. 976, Apr. 2022, doi: 10.3390/pharmaceutics14050976.

2021

  • M. P. Gavini et al., “Suppression of Inflammatory Cardiac Cytokine Network in Rats with Untreated Obesity and Pre-Diabetes by AT2 Receptor Agonist NP-6A4,” Front Pharmacol, vol. 12, p. 693167, Jun. 2021, doi: 10.3389/fphar.2021.693167.

2020

  • H. Sun, L. Pulakat, and D. W. Anderson, “Challenges and New Therapeutic Approaches in the Management of Chronic Wounds,” Curr Drug Targets, vol. 21, no. 12, pp. 1264–1275, 2020, doi: 10.2174/1389450121666200623131200.
  •  
  • N. Sharma, A. M. Belenchia, R. Toedebusch, L. Pulakat, and C. P. Hans, “AT2R agonist NP‐6A4 mitigates aortic stiffness and proteolytic activity in mouse model of aneurysm,” J Cell Mol Med, vol. 24, no. 13, pp. 7393–7404, Jul. 2020, doi: 10.1111/jcmm.15342.
  •  
  • L. Pulakat and C. Sumners, “Angiotensin Type 2 Receptors: Painful, or Not?,” Front Pharmacol, vol. 11, p. 571994, Dec. 2020, doi: 10.3389/fphar.2020.571994.
  •  
  • L. Pulakat and H. H. Chen, “Pro-Senescence and Anti-Senescence Mechanisms of Cardiovascular Aging: Cardiac MicroRNA Regulation of Longevity Drug-Induced Autophagy,” Front Pharmacol, vol. 11, p. 774, May 2020, doi: 10.3389/fphar.2020.00774.

2019

  • N. Sharma et al., “Deficiency of IL12p40 (Interleukin 12 p40) Promotes Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm,” Arterioscler Thromb Vasc Biol, vol. 39, no. 2, pp. 212–223, Feb. 2019, doi: 10.1161/ATVBAHA.118.311969.

2018

  • R. Toedebusch, A. Belenchia, and L. Pulakat, “Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures,” Front Physiol, vol. 9, p. 453, May 2018, doi: 10.3389/fphys.2018.00453.
  •  
  • R. Toedebusch, A. Belenchia, and L. Pulakat, “Cell-Specific Protective Signaling Induced by the Novel AT2R-Agonist NP-6A4 on Human Endothelial and Smooth Muscle Cells,” Front Pharmacol, vol. 9, p. 928, Aug. 2018, doi: 10.3389/fphar.2018.00928.
  •  
  • A. M. Belenchia, M. P. Gavini, R. G. Toedebusch, V. G. DeMarco, and L. Pulakat, “Comparison of Cardiac miRNA Transcriptomes Induced by Diabetes and Rapamycin Treatment and Identification of a Rapamycin-Associated Cardiac MicroRNA Signature,” Oxid Med Cell Longev, vol. 2018, p. 8364608, Dec. 2018, doi: 10.1155/2018/8364608.

2017

  • R. Nistala, A. Raja, and L. Pulakat, “mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats,” Can J Physiol Pharmacol, vol. 95, no. 3, pp. 281–287, Mar. 2017, doi: 10.1139/cjpp-2016-0567.
  •  
  • K. Lum-Naihe et al., “Cardiovascular disease progression in female Zucker Diabetic Fatty rats occurs via unique mechanisms compared to males,” Sci Rep, vol. 7, p. 17823, Dec. 2017, doi: 10.1038/s41598-017-18003-8.
  •  
  • C. Luck, V. G. DeMarco, A. Mahmood, M. P. Gavini, and L. Pulakat, “Differential Regulation of Cardiac Function and Intracardiac Cytokines by Rapamycin in Healthy and Diabetic Rats,” Oxid Med Cell Longev, vol. 2017, p. 5724046, 2017, doi: 10.1155/2017/5724046.
  •  
  • N. Arnold, A. Mahmood, M. Ramdas, P. P. Ehlinger, and L. Pulakat, “Regulation of the cardioprotective adiponectin and its receptor AdipoR1 by salt,” Can J Physiol Pharmacol, vol. 95, no. 3, pp. 305–309, Mar. 2017, doi: 10.1139/cjpp-2016-0570.

2016

  • R. E. Ringling et al., “Loss of Nlrp3 Does Not Protect Mice from Western Diet-Induced Adipose Tissue Inflammation and Glucose Intolerance,” PLoS One, vol. 11, no. 9, p. e0161939, Sep. 2016, doi: 10.1371/journal.pone.0161939.

2015

  • A. Slusarz and L. Pulakat, “The two faces of miR-29,” J Cardiovasc Med (Hagerstown), vol. 16, no. 7, pp. 480–490, Jul. 2015, doi: 10.2459/JCM.0000000000000246.
  •  
  • A. Mahmood and L. Pulakat, “Differential Effects of β-Blockers, Angiotensin II Receptor Blockers, and a Novel AT2R Agonist NP-6A4 on Stress Response of Nutrient-Starved Cardiovascular Cells,” PLoS One, vol. 10, no. 12, p. e0144824, Dec. 2015, doi: 10.1371/journal.pone.0144824.
  •  
  • R. Gul et al., “Regulation of cardiac miR-208a, an inducer of obesity, by Rapamycin and Nebivolol,” Obesity (Silver Spring), vol. 23, no. 11, pp. 2251–2259, Nov. 2015, doi: 10.1002/oby.21227.
  •  
  • S. B. Bender et al., “Mineralocorticoid Receptor Antagonism Treats Obesity-associated Cardiac Diastolic Dysfunction,” Hypertension, vol. 65, no. 5, pp. 1082–1088, May 2015, doi: 10.1161/HYPERTENSIONAHA.114.04912.

2014

  • N. Arnold, P. R. Koppula, R. Gul, C. Luck, and L. Pulakat, “Regulation of Cardiac Expression of the Diabetic Marker MicroRNA miR-29,” PLoS One, vol. 9, no. 7, p. e103284, Jul. 2014, doi: 10.1371/journal.pone.0103284.

2013

  • A. Whaley-Connell et al., “Renin Inhibition and AT1R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling,” Metabolism, vol. 62, no. 6, pp. 861–872, Jun. 2013, doi: 10.1016/j.metabol.2012.12.012.
  •  
  • R. Nistala et al., “Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket,” Am J Physiol Renal Physiol, vol. 304, no. 8, pp. F1105–F1113, Apr. 2013, doi: 10.1152/ajprenal.00127.2012.
  •  
  • C. E. Erickson et al., “The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist,” PLoS One, vol. 8, no. 8, p. e71980, Aug. 2013, doi: 10.1371/journal.pone.0071980.

2012

  • A. T. Whaley-Connell et al., “Mineralocorticoid Receptor-Dependent Proximal Tubule Injury Is Mediated by a Redox-Sensitive mTOR/S6K1 Pathway,” Am J Nephrol, vol. 35, no. 1, pp. 90–100, Jan. 2012, doi: 10.1159/000335079.
  •  
  • A. Whaley-Connell et al., “Combination Direct Renin Inhibition with Angiotensin Type 1 Receptor Blockade improves Aldosterone but does not improve Kidney Injury in the Transgenic Ren2 rat,” Regul Pept, vol. 176, no. 1–3, pp. 36–44, Jun. 2012, doi: 10.1016/j.regpep.2012.03.002.
  •  
  • L. Pulakat, A. R. Aroor, R. Gul, and J. R. Sowers, “Cardiac Insulin Resistance and MicroRNA Modulators,” Exp Diabetes Res, vol. 2012, p. 654904, 2012, doi: 10.1155/2012/654904.
  •  
  • C. H. Mandavia, L. Pulakat, V. DeMarco, and J. R. Sowers, “Over-nutrition and Metabolic Cardiomyopathy,” Metabolism, vol. 61, no. 9, pp. 1205–1210, Sep. 2012, doi: 10.1016/j.metabol.2012.02.013
  •  
  • L. Ma et al., “Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat,” Am J Physiol Heart Circ Physiol, vol. 302, no. 11, pp. H2341–H2351, Jun. 2012, doi: 10.1152/ajpheart.01126.2011.
  •  
  • R. Gul, M. Ramdas, C. H. Mandavia, J. R. Sowers, and L. Pulakat, “RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches,” Cardiorenal Med, vol. 2, no. 4, pp. 268–280, Dec. 2012, doi: 10.1159/000343456.
  •  
  • R. Gul, V. G. DeMarco, J. R. Sowers, A. Whaley-Connell, and L. Pulakat, “Regulation of Overnutrition-Induced Cardiac Inflammatory Mechanisms,” Cardiorenal Med, vol. 2, no. 3, pp. 225–233, Aug. 2012, doi: 10.1159/000339565.
  •  
  • V. G. DeMarco et al., “Overweight female rats selectively breed for low aerobic capacity exhibit increased myocardial fibrosis and diastolic dysfunction,” Am J Physiol Heart Circ Physiol, vol. 302, no. 8, pp. H1667–H1682, Apr. 2012, doi: 10.1152/ajpheart.01027.2011.
  •  
  • A. R. Aroor, C. Mandavia, J. Ren, J. R. Sowers, and L. Pulakat, “Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome,” Cardiorenal Med, vol. 2, no. 2, pp. 87–109, May 2012, doi: 10.1159/000335675.

2011

  • A. Whaley-Connell et al., “Overnutrition and the Cardiorenal Syndrome: Use of a Rodent Model to Examine Mechanisms,” Cardiorenal Med, vol. 1, no. 1, pp. 23–30, Jan. 2011, doi: 10.1159/000322827.
  •  
  • A. Whaley-Connell et al., “Angiotensin II Activation of mTOR Results in Tubulointerstitial Fibrosis through Loss of N-Cadherin,” Am J Nephrol, vol. 34, no. 2, pp. 115–125, Aug. 2011, doi: 10.1159/000329327.
  •  
  • L. Pulakat, V. G. DeMarco, A. Whaley-Connell, and J. R. Sowers, “The Impact of Overnutrition on Insulin Metabolic Signaling in the Heart and the Kidney,” Cardiorenal Med, vol. 1, no. 2, pp. 102–112, May 2011, doi: 10.1159/000327140.
  •  
  • L. Pulakat et al., “Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities,” Am J Physiol Regul Integr Comp Physiol, vol. 301, no. 4, pp. R885–R895, Oct. 2011, doi: 10.1152/ajpregu.00316.2011.
  •  
  • C. Manrique et al., “Nebivolol Improves Insulin Sensitivity in the TGR(Ren2)27 Rat,” Metabolism, vol. 60, no. 12, pp. 1757–1766, Dec. 2011, doi: 10.1016/j.metabol.2011.04.009.
  •  
  • M. R. Hayden et al., “Possible Mechanisms of Local Tissue Renin-Angiotensin System Activation in the Cardiorenal Metabolic Syndrome and Type 2 Diabetes Mellitus,” Cardiorenal Med, vol. 1, no. 3, pp. 193–210, Aug. 2011, doi: 10.1159/000329926.
  •  
  • J. Habibi et al., “Nebivolol Attenuates Redox-Sensitive Glomerular and Tubular Mediated Proteinuria in Obese Rats,” Endocrinology, vol. 152, no. 2, pp. 659–668, Feb. 2011, doi: 10.1210/en.2010-1038.
  •  
  • J. Habibi et al., “Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression,” Am J Physiol Heart Circ Physiol, vol. 300, no. 4, pp. H1484–H1491, Apr. 2011, doi: 10.1152/ajpheart.01000.2010.
  •  
  • V. G. DeMarco et al., “Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat,” Am J Physiol Heart Circ Physiol, vol. 300, no. 1, pp. H181–H190, Jan. 2011, doi: 10.1152/ajpheart.00883.2010.

2010

  • J. Ren, L. Pulakat, A. Whaley-Connell, and J. R. Sowers, “Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease,” J Mol Med (Berl), vol. 88, no. 10, pp. 993–1001, Oct. 2010, doi: 10.1007/s00109-010-0663-9.

2009

  • R. Reyes, L. Pulakat, R. Miledi, and A. Martínez-Torres, “Mammalian AT2 receptors expressed in Xenopus laevis oocytes couple to endogenous chloride channels and stimulate germinal vesicle break down,” Cell Physiol Biochem, vol. 24, no. 1–2, pp. 45–52, 2009, doi: 10.1159/000227812.

2008

  • S. Lahiri, L. Pulakat, and N. Gavini, “Functional participation of a nifH-arsA2 chimeric fusion gene in arsenic reduction by Escherichia coli,” Biochem Biophys Res Commun, vol. 368, no. 2, pp. 311–317, Apr. 2008, doi: 10.1016/j.bbrc.2008.01.086.

2006

  • N. Gavini, S. Tungtur, and L. Pulakat, “Peptidyl-Prolyl cis/trans Isomerase-Independent Functional NifH Mutant of Azotobacter vinelandii,” J Bacteriol, vol. 188, no. 16, pp. 6020–6025, Aug. 2006, doi: 10.1128/JB.00379-06.

2005

  • L. Pulakat, S. Rahman, A. Gray, D. Knowle, and N. Gavini, “Roles of the intracellular regions of angiotensin II receptor AT2 in mediating reduction of intracellular cGMP levels,” Cell Signal, vol. 17, no. 3, pp. 395–404, Mar. 2005, doi: 10.1016/j.cellsig.2004.08.007.
  •  
  • L. Pulakat et al., “Ligand-dependent complex formation between the Angiotensin II receptor subtype AT2 and Na+/H+ exchanger NHE6 in mammalian cells,” Peptides, vol. 26, no. 5, pp. 863–873, May 2005, doi: 10.1016/j.peptides.2004.12.015.
  •  
  • S. Lahiri, L. Pulakat, and N. Gavini, “Functional NifD-K fusion protein in Azotobacter vinelandii is a homodimeric complex equivalent to the native heterotetrameric MoFe protein,” Biochem Biophys Res Commun, vol. 337, no. 2, pp. 677–684, Nov. 2005, doi: 10.1016/j.bbrc.2005.09.105.
  •  
  • P. Kosaraju, L. Pulakat, and N. Gavini, “Analysis of the genome of Azotobacter vinelandii revealed the presence of two genetically distinct group II introns on the chromosome,” Genetica, vol. 124, no. 2–3, pp. 107–115, Jul. 2005, doi: 10.1007/s10709-004-2923-5.

2004

  • L. Pulakat, C. H. Mandavia, and N. Gavini, “Role of Phe308 in the seventh transmembrane domain of the AT2 receptor in ligand binding and signaling,” Biochem Biophys Res Commun, vol. 319, no. 4, pp. 1138–1143, Jul. 2004, doi: 10.1016/j.bbrc.2004.05.092.

2003

  • M.-H. Suh, L. Pulakat, and N. Gavini, “Functional expression of a fusion-dimeric MoFe protein of nitrogenase in Azotobacter vinelandii,” J Biol Chem, vol. 278, no. 7, pp. 5353–5360, Feb. 2003, doi: 10.1074/jbc.M208969200.

2002

  • M. H. Suh, L. Pulakat, and N. Gavini, “Functional expression of the FeMo-cofactor-specific biosynthetic genes nifEN as a NifE-N fusion protein synthesizing unit in Azotobacter vinelandii,” Biochem Biophys Res Commun, vol. 299, no. 2, pp. 233–240, Nov. 2002, doi: 10.1016/s0006-291x(02)02620-7.
  •  
  • L. Pulakat, A. Gray, J. Johnson, D. Knowle, V. Burns, and N. Gavini, “Role of C-terminal cytoplasmic domain of the AT2 receptor in ligand binding and signaling,” FEBS Lett, vol. 524, no. 1–3, pp. 73–78, Jul. 2002, doi: 10.1016/s0014-5793(02)03005-3.
  •  
  • L. Pulakat, S.-H. Lee, and N. Gavini, “Genome of Azotobacter vinelandii: counting of chromosomes by utilizing copy number of a selectable genetic marker,” Genetica, vol. 115, no. 2, pp. 147–158, Jun. 2002, doi: 10.1023/a:1020159116535.
  •  
  • V. Kumar, D. Knowle, N. Gavini, and L. Pulakat, “Identification of the region of AT2 receptor needed for inhibition of the AT1 receptor-mediated inositol 1,4,5-triphosphate generation,” FEBS Lett, vol. 532, no. 3, pp. 379–386, Dec. 2002, doi: 10.1016/s0014-5793(02)03713-4.

2001

  • D. Knowle, J. Kurfis, N. Gavini, and L. Pulakat, “Role of Asp297 of the AT2 receptor in high-affinity binding to different peptide ligands,” Peptides, vol. 22, no. 12, pp. 2145–2149, Dec. 2001, doi: 10.1016/s0196-9781(01)00553-8.

2000

  • D. Knowle, S. Ahmed, and L. Pulakat, “Identification of an interaction between the angiotensin II receptor sub-type AT2 and the ErbB3 receptor, a member of the epidermal growth factor receptor family,” Regul Pept, vol. 87, no. 1–3, pp. 73–82, Feb. 2000, doi: 10.1016/s0167-0115(99)00111-1.

1999

  • C. A. Turner, S. Cooper, and L. Pulakat, “Role of the His273 located in the sixth transmembrane domain of the angiotensin II receptor subtype AT2 in ligand-receptor interaction,” Biochem Biophys Res Commun, vol. 257, no. 3, pp. 704–707, Apr. 1999, doi: 10.1006/bbrc.1999.0207.
  •  
 
  • J. Kurfis, D. Knowle, and L. Pulakat, “Role of Arg182 in the second extracellular loop of angiotensin II receptor AT2 in ligand binding,” Biochem Biophys Res Commun, vol. 263, no. 3, pp. 816–819, Oct. 1999, doi: 10.1006/bbrc.1999.1405.
  •  
  • J. Dittus, S. Cooper, G. Obermair, and L. Pulakat, “Role of the third intracellular loop of the angiotensin II receptor subtype AT2 in ligand-receptor interaction,” FEBS Lett, vol. 445, no. 1, pp. 23–26, Feb. 1999, doi: 10.1016/s0014-5793(99)00085-x.

1998

  • L. Pulakat, A. S. Tadessee, J. J. Dittus, and N. Gavini, “Role of Lys215 located in the fifth transmembrane domain of the AT2 receptor in ligand-receptor interaction,” Regul Pept, vol. 73, no. 1, pp. 51–57, Jan. 1998, doi: 10.1016/s0167-0115(97)01059-8.
 

1994

  • C. Matute, L. Pulakat, C. Río, C. Valcárcel, and R. Miledi, “Properties of angiotensin II receptors in glial cells from the adult corpus callosum,” Proc Natl Acad Sci U S A, vol. 91, no. 9, pp. 3774–3778, Apr. 1994, doi: 10.1073/pnas.91.9.3774.